HCMV-encoded UL128 enhances TNF-α and IL-6 expression and promotes PBMC proliferation through the MAPK/ERK pathway in vitro

Viral Immunology

Volumn 25, Issue 2, 2012, Pages 98-105

  Zheng, Qi ^a   Tao, Ran ^a   Gao, Huihui ^a   Xu, Jun ^a   Shang, Shiqiang ^a   Zhao, Ning ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UL128 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MEDICAL TECHNOLOGY; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; RNA INTERFERENCE; SUPERNATANT; TISSUE CULTURE;

CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA; CYTOMEGALOVIRUS; HUMANS; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL ENVELOPE PROTEINS;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 84859575891     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0064     Document Type: Article

References (29)

1. Onorato IM, Morens DM, and Martone WJ: Epidemiology of cytomegaloviral infections: Recommendations for prevention and control. Rev Infect Dis 1985;7:479-497.
2. Foler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, and Alford CA: The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326: 663-667.
3. Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, and Degli- Esposti MA: The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 2007;85:46-54. (Pubitemid 46067321)
4. Sodergerg-Nauclea C: Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 2006;259:219-246.
5. Zhu J, Quyyumi AA, Norman JJE, Csako G, and Epstein SE: Cytomegalovirus in the pathogenesis of atherosclerosis: The role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 1999;34:1738-1743.
6. Crane MJ, Hokeness-Antonelli KL, and Salazar-Mather TP: Regulation of inflammatory monocyte/macrophage recruitment from the bone marrow during murine cytomegalovirus infection: Role for type I interferons in localized induction of CCR2 ligands. J Immunol 2009;183:2810-2817.
7. Michelson S: Consequences of human cytomegalovirus mimicry. Human Immunol 2004;65:465-475. (Pubitemid 38691129)
8. Loewendorf A, and Benedict CA: Modulation of host innate and adaptive immune defenses by cytomegalovirus: Timing is everything. J Intern Med 2010; 267:483-501.
9. Mocarski ES Jr: Immunomodulation by cytomegaloviruses: Manipulative strategies beyond evasion. Trends Microbiol 2002;10:332-339. (Pubitemid 34756533)
10. Rollins BJ: Chemokines. Blood 1997;90:909-928. (Pubitemid 27314123)
11. Ryckman BJ, Chase MC, and Johnson DC: HCMV gH/gL/ UL128-131 interferes with virus entry into epithelial cells: Evidence for cell type-specific receptors. Proc Natl Acad Sci USA 2008;105:14118-14123.
12. Straschewski S, Patrone M, Walther P, Gallina A, Mertens T, and Frascaroli G: Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration. J Virol 2011;85:5150-5158.
13. Smith MS, Bentz GL, Smith PM, Bivins ER, and Yurochko AD: HCMV activates PI(3)K in monocytes and promotes monocyte motility and transendothelial migration in a PI(3)K-dependent manner. J Leukoc Biol 2004;76:65-76. (Pubitemid 38857173)
14. Johnson RA, Wang X, Ma XL, Huong SM, and Huang ES: Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001;75:6022-6032. (Pubitemid 32553133)
15. Keshet Y and Seger R: The MAP Kinase Signaling Cascades: A system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010; 661:3-39.
16. Juhn SK, Jung MK, and Hoffman MD: The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol 2008;1:117-138.
17. Lagneaux L, Delforge A, Snoeck R, et al.: Imbalance in production of cytokines by bone marrow stromal cells following cytomegalovirus infection. J Infect Dis 1996;174: 913-919. (Pubitemid 26357451)
18. Murayama T, Mukaida N, Sadanari H, Yamaguchi N, and Khalid SA: The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin- 8 gene expression. Bio Chem Bioph Res Co 2000;279:298-304.
19. Docke WD, Kiessling C, Worm M, et al.: Subclinical activation of latent cytomegalovirus (CMV) infection and anti- CMV immune response in patients with atopic dermatitis. Br J Dermatol 2003;148:954-963. (Pubitemid 36750788)
20. Kutza AST, Muhl E, Hackstein H, Kirchner H, and Bein G: High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998;26:1076-1082. (Pubitemid 128751524)
21. Fiorentini S, Luganini A, Dell'Oste V, et al.: Human cytomegalovirus productively infects lymphatic endothelial cells and induces a secretome that promotes angiogenesis and lymphangiogenesis through interleukin-6 and granulocytemacrophage colony-stimulating factor. J Gen Virol 2011;92: 650-660.
22. Lüttichau HR: The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist. J Biol Chem 2010;285:9137-9146.
23. Zhengrong S, Yaohua J, Qiang R, Gengfu X, Rong H, Ying Q, and Yanping M: Genetic variability of human cytomegalovirus UL131A, UL130, UL128 genes in strains from congenitally infected infants. J Wuhan Univ 2006;52:783-788.
24. Miller-Kittrell M, Jiqing S, Penfold M, Richmond A, and Sparer TE: Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1CCMV. Virology 2007; 364:454-465. (Pubitemid 46873706)
25. Cederarva M, Soderberg-Nauclera C, and Odeberg J: HCMV infection of PDCs deviates the NK cell response into cytokine-producing cells unable to perform cytotoxicity. Immunobiology 2009;214:331-341.
26. Ritter T, and Brandt C: Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokines 2000;12:1163-1170. (Pubitemid 30611791)
27. Rodríguez-Berriguete G, Prieto A, Fraile B, and Bouraoui Y: Relationship between IL-6/ERK and NF-jB: A study in normal and pathological human prostate gland. Eur Cytokine Netw 2010;21:241-250.
28. Ruzek MC, Miller AH, Opal SM, Pearce BD, and Biron CA: Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med 1997;185:1185-1192. (Pubitemid 27172899)
29. Fraile-Ramos A, Lira SA, Söderberg-Nauclér C, Martine J, et al.: HCMV-Encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 2010;58:1-10.